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Anti-vascular endothelial growth factor therapy alone and combination with 
photodynamic therapy for polypoidal choroidal vasculopathy yields similar 5-year 
visual outcomes and retinal structural changes; however, macular atrophy tends to be 
more frequent with combination treatment.  




Background/Aims: To evaluate the 5-year visual and anatomical outcomes after 
anti-vascular endothelial growth factor (VEGF) therapy alone or in combination with 
photodynamic therapy (PDT), followed by pro re nata (PRN) anti-VEGF therapy with 
or without PDT, for polypoidal choroidal vasculopathy (PCV). 
Methods: This retrospective, observational study included 61 consecutive patients 
with treatment-naïve symptomatic PCV who were followed for 5 years. Twenty eyes 
(20 patients) initially received PDT and intravitreal injection of ranibizumab (IVR), 
followed by a PRN regimen of anti-VEGF therapy with or without PDT (combination 
group), while 41 eyes (41 patients) initially received only IVR every 3 months, 
followed by a PRN regimen of anti-VEGF monotherapy (IVR group). Macular atrophy 
including the fovea was confirmed using colour fundus photography and 
spectral-domain optical coherence tomography. 
Results: In both groups, the visual acuity (VA) at 1 year was better than the baseline 
VA, whereas the 3-, 4-, and 5-year VA values were similar to the baseline VA. There 
was no significant difference in the 5-year VA, 5-year central retinal thickness, and 
incidence of macular atrophy between the two groups (P=0.63, 0.72, and 0.06, 
respectively). In the combination group, the 5-year VA was correlated with the 5-year 
incidence of macular atrophy (P=0.02, r=0.51). 
Conclusions: A PRN regimen for PCV may have a limited effect for the long-term 
maintenance of improved VA. Macular atrophy may occur more frequently with 
combination therapy and is possibly associated with the 5-year VA. Thus, 
combination therapy should be carefully selected for patients susceptible to macular 
atrophy.  




Symptomatic polypoidal choroidal vasculopathy (PCV), characterized by branching 
vascular networks terminating in polypoidal lesions, is similar to exudative 
age-related macular degeneration (AMD), although it is considered a separate entity 
since its description in 1982.1, 2 Some pathologicak studies have shown that vascular 
endothelial growth factors (VEGFs) are involved in symptomatic PCV development.3, 
4 Therefore, like AMD, symptomatic PCV is treated by intravitreal injection of 
anti-VEGF agents such as pegaptanib, ranibizumab, and aflibercept.5 
 Photodynamic therapy (PDT) with or without intravitreal anti-VEGF therapy is 
also used to treat symptomatic PCV and has favourable effects on visual acuity 
(VA).6-8 In the EVEREST study, the 6-month rate of complete polyp regression was 
higher for patients treated with PDT combined with intravitreal injection of 
ranibizumab (IVR) than in those treated with IVR alone (77.8% vs. 28.6%, P<0.001).9 
Thrombosis of polypoidal lesions following PDT and inhibition of VEGF production 
and vascular permeability via IVR may produce synergetic effects for symptomatic 
PCV treatment. Further, the prospective, randomised, double-masked, multicentre 
EVEREST II study showed that the 12-month VA was better for patients who received 
combination therapy of ranibizumab with PDT than for those who received 
ranibizumab alone.10 However, the invasive effect of PDT on the retina and choroid 
remains concerning.11 
 In clinical settings, anti-VEGF agents are often administered for PCV on a pro 
re nata (PRN) basis, with or without PDT. However, in the long term, VA was reported 
to decrease in patients with AMD who received PRN anti-VEGF therapy.12 In the 
present study, we assessed the 5-year visual and anatomical outcomes after initial 
antii-VEGF therapy alone or in combination with PDT, followed by anti-VEGF therapy 
with or without PDT on a PRN basis, in patients with PCV. 
 
METHODS 
This retrospective study was approved by the institutional review board at Kyoto 
University Graduate School of Medicine, Kyoto, Japan. All study protocols adhered to 
the tenets of the Declaration of Helsinki. All patients provided written informed 
consent for treatment. The institutional review board waived the need for informed 
patient consent for a retrospective review of medical records. 
 
Subjects 
We reviewed the medical records of treatment-naïve eyes affected by symptomatic 
PCV in consecutive patients who were followed for 5 years after receiving initial 
combination therapy of PDT and IVR (Lucentis; Novartis, Buläch, Switzerland) or IVR 
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alone between April 2009 and October 2011 at Kyoto University Hospital. The 
combination group included patients initially treated with a combination of PDT and 
IVR, followed by a PRN regimen of anti-VEGF therapy [ranibizumab or aflibercept 
(Eylea; Bayer, Basel, Switzerland)] with or without PDT. The IVR group included 
patients initially treated with IVR every 3 months, followed by a PRN regimen of 
anti-VEGF monotherapy. The inclusion criteria were as follows: presence of 
exudative or haemorrhagic features involving the macula and a follow-up period of 5 
years, with at least one visit per year after the initial treatment. The exclusion criteria 
were as follows: intraocular surgery, including cataract surgery and vitrectomy, during 
the 5-year follow-up period; high myopia with an axial length (AL) of ≥26.50 mm (or a 
refractive value of ≤−6.00 D in patients without AL data); and the presence or a 
history of other eye diseases. When both eyes of a patient were eligible, the eye 
treated first was included. If both eyes had received treatment on the same day, the 
right eye was included. 
 Before treatment for PCV, all patients had undergone a comprehensive 
ophthalmic examination, including measurement of the best corrected VA using a 
decimal VA (Landolt) chart; measurement of AL using partial coherence 
interferometry (IOLMaster; Carl Zeiss Meditec, Inc., Dublin, CA, USA) or A-mode 
echo analysis (UD-8000; Tomey Corp., Nagoya, Japan) in cases where measurement 
with the IOLMaster was not possible; colour fundus photography (TRC-NW8F; 
Topcon Corp., Tokyo, Japan); spectral domain optical coherence tomography 
(SD-OCT; Spectralis HRA+OCT, Heidelberg Engineering, Heidelberg, Germany; or 
RS-3000 Advance, Nidek Corp., Gamagori, Japan); and fundus fluorescein 
angiography and indocyanine green angiography (ICGA; Heidelberg Retina 
Angiography 2; Heidelberg Engineering). PCV was diagnosed if a branching vascular 
network terminating in polypoidal swelling was detected by retinal specialists on ICGA 
images. 
 
Measurement of the central retinal thickness and greatest linear dimension 
The central retinal thickness was defined as the distance between the inner surface of 
the internal limiting membrane and Bruch's membrane beneath the fovea, and it was 
measured on SD-OCT images by one investigator (MM) using the scanner’s built-in 
tool. The average distance calculated from measurements acquired in horizontal and 
vertical scans was used for analysis. The greatest linear dimension (GLD) was 
measured on ICGA images using the Heidelberg Retina Angiography 2 built-in 
software. 
 
Confirmation of macular atrophy 
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Macular atrophy involving the fovea was confirmed by two investigators (MM, SN) on 
the basis of colour fundus photography and SD-OCT findings at baseline and 5 years 
after treatment (Fig. 1). The criteria for atrophy diagnosis were as follows: thinning of 
the retinal pigment epithelium (RPE) band on OCT, increased signal transmission in 
the choroid on OCT13, and no contradicting findings on colour fundus photography. 
Hyper-refractivity on near-infrared fundus photography was referred. After the 
confirmation of a good interobserver agreement, the values recorded by one 
investigator (MM) were used as representative variables. 
 
Intravitreal injection and photodynamic therapy 
Intravitreal injections were administered in a sterile manner. Prophylactic topical 
antibiotics were regularly applied for 3 days before injection and 3 days to 1 week 
after injection. Three to 4 days after the intravitreal injection, normal-fluence PDT was 
administered using a 689-nm diode laser unit (Visulas PDT system 690S; Carl Zeiss) 
and intravenous verteporfin (Visudyne; Novartis, Basel, Switzerland) in accordance 
with the guidelines for PDT in AMD.14 All polypoidal lesions, including the entire 
branching vascular network detected by ICGA, and the choroidal neovascularization 
detected by fluorescein angiography, were included. Serous pigment epithelium 
detachments were not included in the lesion areas when underlying choroidal 
neovascularization was confirmed to be absent. 
 
Retreatment criteria 
The retreatment criteria were identical to those reported previously.7, 15 Briefly, 
additional combination therapy or PDT was administered as required for exudative 
OCT findings, such as the development or persistence of subretinal fluid, subretinal 
haemorrhage, or active choroidal neovascularization, 3 months after PDT. Additional 
anti-VEGF therapy for exudative findings was administered as required during 
monthly follow-up visits. 
 
Genotyping 
Genotyping data were available for 18 and 35 patients in the combination and IVR 
groups, respectively. Genomic DNA was extracted from peripheral blood samples 
using a DNA extraction kit (QuickGene-610 L; Fujifilm, Minato, Tokyo, Japan). Genes 
encoding age-related maculopathy susceptibility protein 2 (ARMS2) A69S 
rs10490924 and complement factor H I62V rs800292 were genotyped by the TaqMan 
single-nucleotide polymorphism assay method using the ABI PRISM 7700 system 
(Applied Biosystems, Foster City, CA, USA). 
 




The data are presented as mean ± standard deviation or number of eyes, as 
applicable. All VA values were converted to fractional or logarithm of the minimum 
angle of resolution (logMAR) values, where applicable. All statistical analyses were 
performed using SPSS version 21 software (IBM Corp., Armonk, NY, USA). The 
datasets were compared using the t-test, chi-square test, or chi-square trend test, as 
appropriate. Correlations between the 5-year logMAR VA and other parameters were 
determined using Spearman’s rank correlation coefficient analysis. Multiple stepwise 
regression analyses were performed using the 5-year logMAR VA as a dependent 
variable and baseline parameters (Spearman’s correlation coefficients with P-values 
of <0.10) as independent variables. The first combination therapy in the combination 
group and the three initial monthly loading treatments in the IVR group were excluded 
from the number of retreatments. Combination therapy with PDT and intravitreal 
anti-VEGF injection was considered a single session of retreatment. To determine the 
reliability of the measurements, intra-class correlation coefficients (ICCs) for 
interobserver agreement regarding the macular atrophy values recorded by the two 
investigators were calculated. A P-value of <0.05 was considered statistically 
significant. 
 
Subgroup analysis of patients aged ≥70 years at baseline 
The mean patient age in the combination group was significantly higher than that in 
the IVR group. Because patient age could influence the treatment outcome, subgroup 
analyses including patients aged ≥70 years at baseline were performed to detect 
differences between the combination group and an age-matched IVR group. The 
5-year course of VA and number of retreatments in both groups were also analysed. 
 
RESULTS 
In total, 61eyes of 61 consecutive patients were included; 20 eyes of 20 patients and 
41 eyes of 41 patients were divided into the combination and IVR groups, respectively 
(Table 1). There was no significant difference in VA between the two groups at 
baseline or at 1, 2, 3, 4, and 5 years after treatment (Fig. 2). In the combination group, 
the 1-year VA was better than the baseline VA (P=0.003), whereas, the VA values at 2, 
3, 4, and 5 years were not different from the baseline value. In the IVR group, VA at 1 
and 2 years was better than the baseline VA (P=0.003 and 0.02, respectively), 
whereas, that at 3, 4, and 5 years was similar to the baseline VA. The number of 
retreatments in the first year was higher in the IVR group than in the combination 
group (Fig. 2, P=0.02). However, there was no significant intergroup difference in the 
number of retreatments in the subsequent 4 years. The patient age differed between 
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the two groups at baseline (P<0.001); none of the baseline parameters, including sex, 
AL, central retinal thickness, genotype, GLD, and macular atrophy, showed significant 
differences between the two groups. The incidence of macular atrophy was 
marginally higher in the combination group than in the IVR group (P=0.06). ICC (2, 1) 
for interobserver agreement regarding macular atrophy assessment was 0.95, 
indicating excellent agreement. 
 Univariate analysis revealed that the 5-year VA was significantly correlated 
with the baseline VA (P=0.04, r=0.47) and 5-year incidence of macular atrophy 
(P=0.02, r=0.51) in the combination group and age (P<0.001, r=0.53), the baseline 
VA (P<0.001, r=0.58), and the baseline GLD (P=0.003, r=0.45) in the IVR group 
(Table 2). Multivariate analysis revealed that the 5-year VA was strongly correlated 
with the 5-year incidence of macular atrophy (P=0.03, β=0.47) in the combination 
group and the baseline VA (P<0.001, β=0.51) in the IVR group (Table 2). 
 
Subgroup analysis of patients aged ≥70 years at baseline 
The subgroup analysis included 20 and 23 patients from the combination and IVR 
groups, respectively (Table 3). Although the results concerning VA were similar to 
those of the overall group analyses, the total number of retreatments during the 
5-year period was significantly lower in the combination group than in the IVR group 
(P=0.04). The number of retreatments in the first and third years was higher in the 
IVR group than in the combination group (Fig. 2; P=0.02 and 0.003, respectively), 
with no significant intergroup differences in the number of retreatments in the second, 
fourth, and fifth years. 
 
DISCUSSION 
In the present study, the 1-year VA after both combination therapy and anti-VEGF 
monotherapy was better than the corresponding baseline VA for patients with PCV. 
However, in both groups, there was no significant improvement in VA at 3, 4, and 5 
years. PRN anti-VEGF therapy, which is often administered in clinical practice, with or 
without PDT did not achieve a long-term improvement in VA, although the visual 
outcome was superior to that expected in patients with untreated disease.16 Moreover, 
combination therapy could reduce the number of additional treatments in patients 
aged ≥70 years. 
 In a previous 6-year study, the 3-year VA after PRN anti-VEGF therapy for 
patients with PCV was similar to the baseline VA.17 Similarly, a 3-year study 
assessing a PRN regimen for PCV reported that the post-treatment improvement in 
VA persisted until a year after treatment, with VA deterioration.18 These findings are 
consistent with those of the present study. Multicentre prospective studies of AMD 
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have suggested that a PRN regimen is inferior to a monthly injection regimen with 
regard to the persistence of improved VA.19, 20 The SEVEN-UP study reported that the 
7-year VA decreased relative to the baseline VA in patients with AMD treated on a 
PRN basis.12 In clinical practice, PRN monotherapy has a limited effect in terms of the 
long-term maintenance of improved VA in patients with PCV. Therefore, monthly 
injections or a treat-and-extend regimen would be preferable in this scenario. 
 Some retrospective noncomparative studies reported VA improvements at 1 
year in patients with PCV treated by PRN combination therapy with PDT and IVR.6-8 
However, the improvement was not sustained in the second year.8 These results are 
consistent with the present findings. In contrast, a retrospective non-comparative 
study reported a sustained improvement in VA at 3 years after initial combination 
treatment with PDT and intravitreal bevacizumab injection, followed by PDT and 
intravitreal bevacizumab on a PRN basis.21 The EVEREST II study reported that 
combination therapy was superior to IVR monotherapy in terms of the 12-month 
visual outcomes and number of injections.10 Thus, data regarding the long-term 
outcomes of these regimens are desirable. 
 Macular atrophy is a frequent finding in eyes with wet AMD both before and 
after anti-VEGF therapy.13 In the CATT study, newly developed atrophy was observed 
in 26% eyes after a 2-year regimen of monthly IVR and 15% eyes after PRN IVR 
treatment.22 There is no evidence suggesting that PDT increases the risk of macular 
atrophy, excluding high myopia.23 In the present study, newly developed macular 
atrophy including the fovea was observed in 45% eyes in the combination group and 
22% eyes in the IVR group (P=0.06). PDT damages the choriocapillary endothelium 
within a short interval.24 We consider that the damage may affect macular atrophy 
development in the long term. The 5-year incidence of macular atrophy including the 
fovea was significantly correlated with the 5-year VA in our combination group. These 
results suggest that combination therapy should be carefully chosen for patients who 
are potentially susceptible to macular atrophy, and that it is better to administer PDT 
in regions excluding the fovea. 
 The baseline GLD was associated with the 5-year VA in our IVR group. 
Tsujikawa et al. reported that the post-treatment VA in patients with PCV was worse in 
the presence of large vascular lesions measuring more than one disc area.25 Our 
findings for the IVR group are consistent with these findings,25 and those of another 
3-year study.18 However, GLD was not associated with VA in our combination group; 
this suggests that the effect of IVR monotherapy on the 5-year VA may be limited for 
eyes with PCV exhibiting an increased GLD before treatment. 
 The present study has some limitations. First is the retrospective design. To 
our knowledge, there is only one prospective trial on this subject, i.e. the EVEREST 
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study, which recently reported its 12-month data.10 Second, the mean patient age in 
the combination group was significantly higher than that in the IVR group, although 
we performed a subgroup analysis and found no significant influence of age on the 
findings. 
 In conclusion, our findings suggest that a PRN regimen for PCV may have a 
limited effect for the long-term maintenance of improved VA. Macular atrophy may 
occur more frequently with combination therapy and is possibly associated with 
5-year VA. Thus, combination therapy should be carefully selected for patients who 
susceptible to macular atrophy.  
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Figure 1. Representative images showing 5-year changes in macular atrophy after 
anti-vascular endothelial growth factor treatment with or without photodynamic 
therapy 
 
Colour fundus photographs(A, B) and SD-OCT images (C, D) acquired at baseline (A, 
C) and 5 years (B, D) after combination treatment for a 76-year-old woman with PCV 
(combination group) 
 
Colour fundus photographs (E, F) and SD-OCT images (G, H) acquired at baseline (E, 
G) and 5 years (F, H) after exclusive treatment with IVR for a 77-year-old man with 
PCV (IVR group) 
 
While the 5-year colour fundus photographs (B, F) show hypopigmentation and 
visible choroidal vessels in the macula, the SD-OCT images (D, H) show highly 
reflective choroidal signals because of retinal thinning and hypopigmentation of the 
retinal pigment epithelium. 
 
SD-OCT, spectral domain optical coherence tomography; PCV, polypoidal choroidal 
vasculopathy;.IVR, intravitreal injection of ranibizumab 
Combination group: initial treatment with a combination of photodynamic therapy and 
IVR 
IVR group: initially treatment with IVR only 
 
Figure 2. Annual changes in VA (logMAR) and the number of retreatments during a 
5-year follow-up period after anti-vascular endothelial growth factor treatment with or 
without photodynamic therapy for polypoidal choroidal vasculopathy 
 
(A) In the combination group, the 1-year VA is significantly better than the baseline 
VA (*), whereas VA at 2, 3, 4, and 5 years after treatment is not significantly different 
from the baseline VA. In the IVR group, VA at 1 and 2 years after treatment is 
significantly better than the baseline VA (+), whereas that at 3, 4, and 5 years is not 
significantly different from the baseline VA. There is no significant difference in VA 
between the two groups at any time point. 
 
(B) Findings of subgroup analysis including patients aged ≥70 years 
All patients in the combination group were included in this subgroup analysis. 
In the IVR group, VA at 1 year after treatment is significantly better than the baseline 
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VA (+), whereas that at 2, 3, 4, and 5 years is not significantly different from the 
baseline VA. There is no significant difference in VA between the two groups at any 
time point. 
 
(C) In the first year, the number of retreatments is higher in the IVR group than in the 
combination group (*), with no significant differences between groups in the 
subsequent 4 years. 
 
(D) Findings of subgroup analysis including patients aged ≥70 years 
The numbers of retreatments in the first and third years is significantly higher in the 
IVR group than in the combination group (*), with no significant differences between 
groups in the second, fourth, and fifth years. 
 
logMAR, logarithm of the minimum angle of resolution; VA, visual acuity; IVR, 
intravitreal injection of ranibizumab 
Combination group: initial treatment with a combination of photodynamic therapy and 
IVR 
IVR group: initially treatment with IVR only  
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Table 1. Comparison between the combination and IVR groups 
 
Combination Group IVR Group P-value 
Number of eyes (patients) 20 (20) 41 (41) 
 
Age, years 






Sex (M/F), n 11/9 30/12 0.13# 
Axial length, mm 23.09±0.71a 23.77±1.46b 0.06 
LogMAR visual acuity 
Baseline 0.41±0.27 0.40±0.46 0.95 
1-year 0.26±0.29 0.29±0.45 0.78 
2-year 0.31±0.32 0.31±0.46 0.97 
3-year 0.33±0.39 0.32±0.46 0.95 
4-year 0.46±0.46 0.36±0.49 0.47 
5-year 0.47±0.40 0.41±0.49 0.63 
Central retinal 
thickness, μm 
Baseline  433.1±135.2 363.3±134.1c 0.07 
5-year  237.3±114.9 225.1±129.0d 0.72 
Genotyping, n 
ARMS2 A69S (GG/GT/TT) 4/8/6e 10/10/15f 0.84## 
CFH I62V (AA/AG/GG) 3/9/6g 3/12/20h 0.10## 
GLD at baseline, μm 3785±1086 3974±2121 0.71 
Number of 
retreatments 
Total 5.3±6.4 9.2±10.5 0.14 
Year 1 0.5±0.9 1.7±2.2 0.003* 
Year 2 1.1±1.8 1.6±2.4 0.29 
Year 3 0.8±1.1 2.0±2.8 0.02* 
Year 4 1.5±2.4 2.0±2.7 0.45 
Year 5 1.6±2.3 1.8±2.4 0.70 
Additional number of PDT sessions 1.3±1.3 0 - 
Macular atrophy 
including the fovea, n 
Baseline 0 4 0.15# 
5-year 9 13 0.31# 
New 9 9 0.06# 
Intravitreal gas injection for subretinal haemorrhage, n 1 1 0.55 
Data are presented as means ± standard deviations or number of eyes, as applicable. 
Combination group: initial treatment with a combination of PDT and IVR 
IVR group: initial treatment with IVR only 
logMAR, logarithm of the minimal angle of resolution; ARMS2, age-related maculopathy susceptibility protein 2; CFH, 
complement factor H; GLD, greatest linear dimension; PDT, photodynamic therapy; IVR, intravitreal injection of ranibizumab 
In measurements indicated by a, b, c, d, e, f, g, and h, data are missing for one, three, four, one, two, six, two, and six patients, 
respectively. 




#chi-square test, ##chi-square trend test; the remaining: t-test 
*statistically significant (P<0.05) 




Table 2. Correlation between the 5-year logMAR VA and other parameters 
 
Combination Group 
(n = 20) 
IVR Group 









 P-value r P-value β P-value r P-value β 
Age 0.48 - - - < 0.001* 0.53 0.002* 0.37 
Sex 0.39 - - - 0.44 - - - 
Axial length 0.38a - - - 0.58b - - - 
LogMAR visual acuity at baseline 0.04* 0.47 0.03* 0.45 < 0.001* 0.58 < 0.001* 0.51 
Central retinal 
thickness 
Baseline 0.43 - - - 0.051c 0.32 0.11 - 
5-Year 0.37 - - - 0.73d - - - 
Genotyping 
ARMS2 A69S 0.66e - - - 0.67f - - - 
CFH I62V 0.051g −0.47 0.13 - 0.63h - - - 
GLD at baseline 0.80 - - - 0.003* 0.45 0.03* 0.25 
Number of retreatments 0.51 - - - 0.50 - - - 
Total number of PDT 0.40 - - - - - - - 
Macular atrophy 
including the fovea 
Baseline 0.20 - - - 0.13 - - - 
5-year 0.02* 0.51 0.03* 0.47 0.23 - - - 
Combination group: initial treatment with PDT in combination with IVR 
IVR group: initial treatment with IVR onlylogMAR, logarithm of the minimum angle of resolution; ARMS2, age-related maculopathy 
susceptibility protein 2; CFH, complement factor H; GLD, greatest linear dimension; PDT, photodynamic therapy; IVR, intravitreal 
injection of ranibizumab 
In measurements indicated by a, b, c, d, e, f, g, and h, data were missing for 1, 3, 4, 1, 2, 6, 2, and 6 patients, respectively. 
In the IVR group, the central retinal thickness at baseline and the 5-year follow-up visit could not be measured because of 
substantial subretinal haemorrhage in four patients and fibrous scarring in one patient. 
Genotyping: 0, non-risk homozygous; 1, heterozygous; 2, risk homozygous 
Macular atrophy: 0, absent; 1, present 
*statistically significant (P<0.05) 
Macular atrophy: 0, absent; 1, present 
*statistically significant (P<0.05). 
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Table 3. Comparison between patients aged ≥70 years at baseline in the combination and IVR groups 
 
Combination Group IVR Group P-value 
Number of eyes (patients) 20 (20) 23 (23) 
 
Age, years 






Sex (M/F), n 11/9 18/5 0.10# 
Axial length, mm 23.09±0.71a 23.52±1.54b 0.28 
LogMAR visual 
acuity 
Baseline 0.41±0.27 0.44±0.48 0.81 
1-year 0.26±0.29 0.33±0.40 0.50 
2-year 0.31±0.32 0.38±0.43 0.55 
3-year 0.33±0.39 0.44±0.46 0.40 
4-year 0.46±0.46 0.47±0.47 0.93 
5-year 0.47±0.40 0.53±0.45 0.67 
Central retinal 
thickness, μm 
Baseline  433.1±135.2 364.0±150.8c 0.13 
5-year  237.3±114.9 210.7±153.0 0.53 
Genotyping, n 
ARMS2 A69S (GG/GT/TT) 4/8/6d 8/5/4e 0.19## 
CFH I62V (AA/AG/GG) 3/9/6f 1/8/8g 0.30## 
GLD at baseline, μm 3785±1086 4359±1941 0.25 
Number of 
retreatments 
Total 5.3±6.4 11.8±11.7 0.04* 
Year 1 0.5±0.9 1.5±1.8 0.02* 
Year 2 1.1±1.8 2.3±2.6 0.08 
Year 3 0.8±1.1 2.9±3.0 0.003* 
Year 4 1.5±2.4 2.6±3.1 0.18 
Year 5 1.6±2.3 2.3±2.8 0.37 
Additional number of PDT sessions 1.3±1.3 0 - 
Macular atrophy 
including the fovea, 
n 
Baseline 0 4 0.11# 
5-year 9 9 0.76# 
New 9 5 0.19# 
Intravitreal gas injection for subretinal haemorrhage, n 1 1 0.72# 
Data are presented as means ± standard deviations or number of eyes, as applicable. 
Combination group: initial treatment with PDT in combination with IVR 
IVR group: initial treatment with IVR only 
logMAR, logarithm of the minimum angle of resolution; ARMS2, age-related maculopathy susceptibility protein 2; CFH, 
complement factor H; GLD, greatest linear dimension; PDT, photodynamic therapy; IVR, intravitreal injection of 
ranibizumab 
In measurements indicated by a, b, c, d, e, f, and g, data are missing for one, three, one, two, six, two, and six patients, 





#chi-square test; ##chi-square trend test; the remaining: t-test 
*statistically significant (P<0.05) 
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